Welcome to our dedicated page for Dariohealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on Dariohealth stock.
DarioHealth Corp. (NASDAQ: DRIO) is a digital health company focused on multi-chronic condition management through a user-centric digital therapeutics platform, and its news flow reflects developments across technology, clinical evidence, commercial traction and corporate strategy. News items frequently describe how Dario’s platform and suite of solutions deliver personalized, dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
Recent announcements have highlighted the launch of DarioIQ™, an artificial intelligence layer integrated into the Dario Health app. This AI capability, initially introduced for a cohort of hypertension members in a direct-to-consumer setting, is described as a clinically aligned, conversational layer that integrates behavioral insights, real-time biometric interpretation and personalized guidance while working alongside Dario’s human coaching framework. The company’s news coverage explains how DarioIQ™ is intended to enhance chronic condition management without replacing human-centered guidance.
DarioHealth’s news also emphasizes peer-reviewed clinical and economic evidence. Publications in JMIR Cardio and the Journal of Medical Internet Research (JMIR) have been featured in press releases, detailing studies of data-driven digital nudges for blood pressure management and analyses of healthcare utilization and medical costs among adults with type 2 diabetes using Dario’s platform compared to matched individuals receiving usual care. These articles are presented as supporting evidence for Dario’s ability to impact outcomes and healthcare burden.
Investors and observers following DRIO news will also see updates on employer and health plan adoption, including the signing of new employer clients and expansion of Dario’s commercial pipeline, as well as financing events such as private placements and strategic reviews initiated by the Board of Directors. Together, these news items provide context on how DarioHealth develops its technology, validates its approach through research and pursues growth with payers, employers and partners.
DarioHealth Corp. (Nasdaq: DRIO) announced an agreement to acquire assets from Physimax Technologies Ltd., specializing in computer vision technology for musculoskeletal screening. This technology, used by organizations like the NBA and U.S. military, offers automated injury assessments and personalized training programs. The acquisition involves issuing up to 256,660 shares and a cash payment of $500,000, alongside assuming liabilities of approximately $1,020,000. DarioHealth aims to enhance its offerings, promoting growth in musculoskeletal health care while reducing reliance on human support.
DarioHealth Corp. (NASDAQ-CM: DRIO) announced a contract with a large regional health plan to provide its digital therapeutic solution for diabetes to eligible Medicaid members in the mid-Atlantic region. Expected to contribute to revenue in Q2 2022, this partnership aims to improve access to innovative diabetes care and reduce medical costs for Medicaid participants, who face significantly higher healthcare expenses. DarioHealth’s digital therapeutics platform addresses various chronic conditions, emphasizing personalized experiences and behavior change for better health outcomes.
DarioHealth Corp. (Nasdaq: DRIO) is set to host an investor webinar on January 19, 2022, at 8 am ET, focusing on emerging digital health trends. The event will feature insights from industry experts Sari Kaganoff and David Kaplan, along with DarioHealth executives detailing the company's digital therapeutics platform and 2021 achievements. DarioHealth aims to transform healthcare with its AI-powered platform addressing chronic conditions like diabetes and hypertension. To register, visit their website.
DarioHealth Corp. (Nasdaq: DRIO) announced a strategic partnership with a leading employer benefits brokerage to provide its digital therapeutic solutions for diabetes, hypertension, and musculoskeletal health. This new employee health benefits product will be available to over 2,300 small business clients starting early 2022. DarioHealth was selected for its proven engagement and cost-effective clinical results, positioning it as the exclusive chronic condition management solution in the benefits package, potentially benefiting millions of small business employees.
DarioHealth Corp. (Nasdaq: DRIO) announced its Q3 2021 financial results, showcasing a remarkable 176% revenue growth year-over-year, reaching $5.6 million. Pro-forma gross margin improved to 45% from 26.9% a year prior. Despite robust revenue growth, the company reported an operating loss of $22.5 million, up 240.8% from Q3 2020. Dario secured 47 contracts to date, with a billion-dollar pipeline, primarily focused on multi-condition digital health solutions. The firm is well-funded with $51.3 million in cash, supporting its growth strategy in the competitive digital therapeutics market.
DarioHealth Corp. (Nasdaq: DRIO) has appointed Jerrod Helms as Chief Commercial Officer to enhance its growth in employer, payer, and provider markets amid significant commercial acceleration. Mr. Helms, with extensive sales leadership experience in healthcare, joins from Ginger and Headspace. The appointment aims to capitalize on rising demand for Dario's multi-chronic digital therapeutic solutions. The company is optimistic about expanding its market presence and achieving accelerated growth moving into 2022.
FAQ
What is the current stock price of Dariohealth (DRIO)?
What is the market cap of Dariohealth (DRIO)?
